-
Exploring blood biomarkers for disease progression and treatment response in multiple sclerosis
van Lierop, Z. Y. G. J., 2025, 252 p.Research output: PhD thesis › Research HvA, graduation HvA (not in use)
-
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
Rodriguez-Mogeda, C., van Lierop, Z. Y. G. J., van der Pol, S. M. A., Coenen, L., Hogenboom, L., Kamermans, A., Rodriguez, E., van Horssen, J., van Kempen, Z. L. E., Uitdehaag, B. M. J., Teunissen, C. E., Witte, M. E., Killestein, J. & de Vries, H. E., Dec 2023, In: Journal of Neuroinflammation. 20, 1, p. 215 215.Research output: Contribution to journal › Article › Academic › peer-review
-
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Toorop, A. A., van Lierop, Z. Y., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L., Kloosterziel, M. E. & Arnoldus, E. P. & 15 others, , 14 Nov 2023, (E-pub ahead of print) In: Journal of neurology, neurosurgery, and psychiatry.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
